Skip to main content

MIRM

Stock
Health Care
Biotechnology

Performance overview

MIRM Price
Price Chart

Forward-looking statistics

Beta
0.87
Risk
47.12%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.

Company info

SectorHealth Care
IndustryBiotechnology
Employees231
Market cap$1.2B

Fundamentals

Enterprise value$2.6B
Revenue$379.3M
Revenue per employee—
Profit margin-20.39%
Debt to equity135.97

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.61
Dividend per share—
Revenue per share$7.90
Avg trading volume (30 day)$23M
Avg trading volume (10 day)$25M
Put-call ratio—

Macro factor sensitivity

Growth+6.1
Credit+14.7
Liquidity-6.4
Inflation+1.1
Commodities+0.8
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio-57.82
Price to sales6.57
P/E Ratio-57.82
Enterprise Value to Revenue6.75
Price to book10.66

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend day—

News

Mirum Gains 35% in 3 Months: How Should You Play the Stock?

MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.

Zacks Investment Research (July 17, 2025)
Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (June 6, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free